Abstract
Receptor tyrosine kinases (RTKs) are known to be key regulators of cancer cell proliferation, migration, invasion and metastatic spread. Ligand-binding to the extracellular domain triggers canonical activation of the intracellular tyrosine kinase domain. In contrast, it has become evident that RTKs are also regulated by non-canonical tyrosine kinaseindependent mechanisms via phosphorylation of their serine/threonine residues. In this review, I mainly introduce our recent findings on the non-canonical regulation of epidermal growth factor receptor (EGFR), ErbB2 and erythropoietin-producing hepatocellular receptor A2 (EphA2), and discuss the roles of non-canonical activation of RTKs in cancer progression and resistance to targeted cancer agents. Further characterization of non-canonical regulation will contribute to the development of new target cancer therapies.
Original language | English |
---|---|
Pages (from-to) | 141-144 |
Number of pages | 4 |
Journal | Yakugaku Zasshi |
Volume | 137 |
Issue number | 2 |
DOIs | |
State | Published - 2017 |
Keywords
- Cancer
- Cytokine
- Epidermal growth factor receptor
- Erythropoietin-producing hepatocellular receptor A2
- Growth factor
- Receptor tyrosine kinase
ASJC Scopus subject areas
- Pharmacology
- Pharmaceutical Science